CR20180097A - ANTIBODY ANTI-CD154 WITH IMPROVED UNION, FUNCTIONALITY AND SECURITY CHARACTERISTICS AND USE IN HUMAN IMMUNOTHERAPY - Google Patents
ANTIBODY ANTI-CD154 WITH IMPROVED UNION, FUNCTIONALITY AND SECURITY CHARACTERISTICS AND USE IN HUMAN IMMUNOTHERAPYInfo
- Publication number
- CR20180097A CR20180097A CR20180097A CR20180097A CR20180097A CR 20180097 A CR20180097 A CR 20180097A CR 20180097 A CR20180097 A CR 20180097A CR 20180097 A CR20180097 A CR 20180097A CR 20180097 A CR20180097 A CR 20180097A
- Authority
- CR
- Costa Rica
- Prior art keywords
- functionality
- antibody anti
- security characteristics
- human immunotherapy
- improved union
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
Abstract
Se proporcionan en la presente memoria anticuerpos anti-CD154 mejorados que tienen una potencia terapéutica, una semivida in vivo mejoradas y una unión a FcR y/o una unión/activación del complemento abolidas. Se describe en la presente memoria el uso de estos anticuerpos para inducir tolerancia y tratar enfermedades inmunitarias que incluyen autoinmunidad, inflamación, receptores de trasplantes, fibrosis y trastornos alérgicosEnhanced anti-CD154 antibodies are provided herein having improved therapeutic potency, an in vivo half-life and an FcR binding and / or an abolished complement binding / activation. The use of these antibodies to induce tolerance and treat immune diseases including autoimmunity, inflammation, transplant recipients, fibrosis and allergic disorders is described herein.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562192269P | 2015-07-14 | 2015-07-14 | |
| US201562197966P | 2015-07-28 | 2015-07-28 | |
| US201662277201P | 2016-01-11 | 2016-01-11 | |
| PCT/US2016/042074 WO2017011544A1 (en) | 2015-07-14 | 2016-07-13 | Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20180097A true CR20180097A (en) | 2018-05-25 |
Family
ID=57757587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20180097A CR20180097A (en) | 2015-07-14 | 2016-07-13 | ANTIBODY ANTI-CD154 WITH IMPROVED UNION, FUNCTIONALITY AND SECURITY CHARACTERISTICS AND USE IN HUMAN IMMUNOTHERAPY |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10874738B2 (en) |
| EP (2) | EP3331548B1 (en) |
| JP (4) | JP6826113B2 (en) |
| KR (2) | KR102825142B1 (en) |
| CN (2) | CN114671952A (en) |
| AU (3) | AU2016294417B2 (en) |
| CL (1) | CL2018000103A1 (en) |
| CO (1) | CO2018001363A2 (en) |
| CR (1) | CR20180097A (en) |
| DO (1) | DOP2018000018A (en) |
| EA (1) | EA201890297A1 (en) |
| EC (1) | ECSP18009949A (en) |
| GT (1) | GT201800018A (en) |
| HK (1) | HK1249735A1 (en) |
| IL (3) | IL310460A (en) |
| MX (2) | MX2018000548A (en) |
| MY (2) | MY196991A (en) |
| PE (1) | PE20180741A1 (en) |
| PH (1) | PH12018500098A1 (en) |
| SG (1) | SG10201913431QA (en) |
| TN (1) | TN2018000021A1 (en) |
| WO (1) | WO2017011544A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201890297A1 (en) * | 2015-07-14 | 2018-06-29 | Иммьюнекст, Инк. | ANTIBODY TO CD154, possessing improved characteristics of binding, function and safety, and its use in human immunotherapy |
| CN108473561B (en) | 2015-11-27 | 2022-12-16 | 埃博灵克斯股份有限公司 | Polypeptide inhibiting CD40L |
| US11505610B2 (en) | 2018-04-06 | 2022-11-22 | Atyr Pharma, Inc. | Compositions and methods comprising anti-NRP2 antibodies |
| WO2020056162A1 (en) * | 2018-09-12 | 2020-03-19 | Oregon Health & Science University | Detecting and/or subtyping circulating hybrid cells that correlate with stage and survival |
| WO2020068723A1 (en) * | 2018-09-24 | 2020-04-02 | Janssen Biotech, Inc. | Method of providing safe administration of an anti-cd154 antibody |
| CN115227824A (en) * | 2018-11-12 | 2022-10-25 | 中南大学湘雅二医院 | Application of immune checkpoint inhibitors in the preparation of drugs for the treatment of glaucoma and other diseases related to ocular immune damage mechanisms |
| CN114173772A (en) * | 2019-04-12 | 2022-03-11 | 托尼克斯医药控股公司 | Inhibitors of CD40-CD154 binding |
| CN114746120B (en) | 2019-10-03 | 2024-07-30 | Atyr医药公司 | Compositions and methods comprising anti-NRP 2 antibodies |
| CN113488170B (en) * | 2021-07-02 | 2023-07-25 | 温州医科大学 | Method for constructing acute anterior uveitis recurrence risk prediction model and related equipment |
| EP4382537A4 (en) * | 2021-07-30 | 2025-07-23 | Seoul Nat Univ R&Db Foundation | ANTI-CD154 ANTIBODIES AND USE THEREOF |
| WO2023008982A1 (en) * | 2021-07-30 | 2023-02-02 | 서울대학교산학협력단 | Anti cd154 antibody and use thereof |
| EP4688856A1 (en) | 2023-04-03 | 2026-02-11 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
| AU2024262779A1 (en) | 2023-04-28 | 2025-12-11 | Fortvita Biologics Inc. | Anti-cd40l antibody and use thereof in treatment of human autoimmune diseases |
| US20240392022A1 (en) * | 2023-05-22 | 2024-11-28 | Genzyme Corporation | Treatment of multiple sclerosis with anti-cd40l antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995006666A1 (en) | 1993-09-02 | 1995-03-09 | Trustees Of Dartmouth College | Anti-gp39 antibodies and uses therefor |
| US6440418B1 (en) * | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6444018B1 (en) | 1998-06-25 | 2002-09-03 | Xerox Corporation | Phase change ink carrier compositions containing anhydride/amino alcohol-based adducts |
| GB0006398D0 (en) * | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
| TR200300478T2 (en) | 2000-10-13 | 2004-10-21 | Biogen Inc. | Humanized antiLT-ß-R antibodies |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| DE602004029252D1 (en) * | 2003-06-13 | 2010-11-04 | Biogen Idec Inc | AGLYCOSYL-ANTI-CD154 (CD40-LIGAND) ANTIBODIES AND THEIR USES |
| CN1871259A (en) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | Improved antibodies having altered effector function and methods for making the same |
| WO2006104989A2 (en) | 2005-03-29 | 2006-10-05 | Verenium Corporation | Altered antibody fc regions and uses thereof |
| SG196697A1 (en) * | 2007-03-22 | 2014-02-13 | Biogen Idec Inc | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof |
| WO2012138768A2 (en) * | 2011-04-04 | 2012-10-11 | Trustees Of Dartmouth College | Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies |
| US9321833B2 (en) * | 2011-04-04 | 2016-04-26 | The Trustees Of Dartmouth College | Methods of therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties |
| EA201890297A1 (en) * | 2015-07-14 | 2018-06-29 | Иммьюнекст, Инк. | ANTIBODY TO CD154, possessing improved characteristics of binding, function and safety, and its use in human immunotherapy |
-
2016
- 2016-07-13 EA EA201890297A patent/EA201890297A1/en unknown
- 2016-07-13 HK HK18109202.5A patent/HK1249735A1/en unknown
- 2016-07-13 EP EP16825103.1A patent/EP3331548B1/en active Active
- 2016-07-13 MX MX2018000548A patent/MX2018000548A/en unknown
- 2016-07-13 IL IL310460A patent/IL310460A/en unknown
- 2016-07-13 JP JP2018521475A patent/JP6826113B2/en active Active
- 2016-07-13 CN CN202210146798.5A patent/CN114671952A/en active Pending
- 2016-07-13 MY MYPI2018700104A patent/MY196991A/en unknown
- 2016-07-13 CN CN201680053004.3A patent/CN108135969B/en active Active
- 2016-07-13 WO PCT/US2016/042074 patent/WO2017011544A1/en not_active Ceased
- 2016-07-13 US US15/744,379 patent/US10874738B2/en active Active
- 2016-07-13 KR KR1020187004571A patent/KR102825142B1/en active Active
- 2016-07-13 PE PE2018000072A patent/PE20180741A1/en unknown
- 2016-07-13 EP EP26164394.4A patent/EP4732909A2/en active Pending
- 2016-07-13 IL IL297907A patent/IL297907B2/en unknown
- 2016-07-13 TN TNP/2018/000021A patent/TN2018000021A1/en unknown
- 2016-07-13 CR CR20180097A patent/CR20180097A/en unknown
- 2016-07-13 AU AU2016294417A patent/AU2016294417B2/en active Active
- 2016-07-13 IL IL256800A patent/IL256800B2/en unknown
- 2016-07-13 SG SG10201913431QA patent/SG10201913431QA/en unknown
- 2016-07-13 KR KR1020257020732A patent/KR20250099272A/en active Pending
- 2016-07-13 MY MYPI2020006781A patent/MY203911A/en unknown
-
2018
- 2018-01-11 PH PH12018500098A patent/PH12018500098A1/en unknown
- 2018-01-12 DO DO2018000018A patent/DOP2018000018A/en unknown
- 2018-01-12 MX MX2023014921A patent/MX2023014921A/en unknown
- 2018-01-12 GT GT201800018A patent/GT201800018A/en unknown
- 2018-01-12 CL CL2018000103A patent/CL2018000103A1/en unknown
- 2018-02-09 EC ECIEPI20189949A patent/ECSP18009949A/en unknown
- 2018-02-12 CO CONC2018/0001363A patent/CO2018001363A2/en unknown
-
2020
- 2020-11-23 US US17/101,139 patent/US11596689B2/en active Active
-
2021
- 2021-01-13 JP JP2021003152A patent/JP2021063129A/en active Pending
-
2022
- 2022-11-02 AU AU2022263520A patent/AU2022263520B2/en active Active
-
2023
- 2023-02-01 US US18/162,769 patent/US20240000929A1/en active Pending
- 2023-07-05 JP JP2023110414A patent/JP7605914B2/en active Active
-
2024
- 2024-12-12 JP JP2024217195A patent/JP2025038055A/en active Pending
-
2025
- 2025-09-05 AU AU2025226796A patent/AU2025226796A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP18009949A (en) | ANTI-CD154 ANTIBODY WITH IMPROVED BINDING, FUNCTIONALITY AND SAFETY CHARACTERISTICS AND USE IN HUMAN IMMUNOTHERAPY | |
| CO2019012210A2 (en) | Anti-trem2 antibodies and methods of using them | |
| CL2019000277A1 (en) | Joint treatment against cancer. | |
| CL2019002850A1 (en) | Combination therapies targeting pd-1, tim-3, and lag-3. | |
| CL2017003261A1 (en) | Factor xi antibodies and methods of use | |
| MX2019008350A (en) | Subcutaneous her2 antibody formulations. | |
| EA201790334A1 (en) | Conjugates Anti-CDH6 Antibodies With Medicinal Products | |
| MX2018014175A (en) | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE. | |
| CL2017001920A1 (en) | Human antibodies against Ebola virus glycoprotein | |
| ECSP18096095A (en) | ALPHA-SINUCLEIN ANTIBODIES AND USES OF THEM | |
| MX2018002990A (en) | USE OF PASTEURIZED AKKERMANSIA TO TREAT METABOLIC DISORDERS. | |
| CL2019003211A1 (en) | Anti-garp-tgf-ß antibodies. | |
| BR112015020911A2 (en) | antibody, use of a combination and treatment method | |
| PE20161210A1 (en) | ANTI-MCAM ANTIBODIES AND ASSOCIATED METHODS OF USE | |
| CL2016002794A1 (en) | Peptide vaccine comprising a mutant ras peptide and a chemotherapeutic agent | |
| EA201792300A1 (en) | COMBINATIONS OF IMMUNOCONGAGED TO CD37 AND ANTIBODIES TO CD20 | |
| MX389320B (en) | ANTI-TNFRSF25 ANTIBODIES | |
| MX2018004177A (en) | Combination therapy for the treatment of cancer. | |
| CR20150585A (en) | ANTI-IGF-1R ANTIBODIES WITH ABOLITION OF THE UNION TO THE FCRN AND ITS USE IN THE TREATMENT OF VASCULAR EYE DISEASES | |
| MX2018005825A (en) | MODIFIED IMMUNE CELLS AND USES OF THE SAME. | |
| CL2017000212A1 (en) | Angiopoietin 4-like anti-protein antibodies and methods of use | |
| MX2015015232A (en) | Monoclonal antibody directed against cxcr5. | |
| UY36261A (en) | ANTIBODIES ANTI PROTEIN SIMILAR TO ANGIOPOYETINA-4 (ANGPTL4) AND METHODS OF USE | |
| CR20160369A (en) | COMPOSITIONS FOR USE IN THE TREATMENT OF ALLERGIC AFFECTIONS | |
| EA201691964A1 (en) | CONJUGATES FOR DELIVERY OF MEDICINES FOR THE TREATMENT OF SUSTAINABLE FORMS OF CANCER AND FOR USE IN COMBINED THERAPY |